Treatment of Insomnia with Zaleplon in HIV+ Significantly Improves Sleep and Depression.

ABSTRACT: More than 50% of individuals who are HIV positive report insomnia, which can reduce HIV treatment adherence, impair quality of life, and contribute to metabolic dysfunction. Major depressive disorder is also highly comorbid in this population, leading to further impairment. There is evidence that treating insomnia may improve not only sleep, but depression and metabolic function, as well. The present study aimed to examine the effects of pharmacotherapeutic treatment of insomnia on sleep, depression, and metabolic functioning in individuals with HIV. 20 individuals with asymptomatic seropositive HIV and comorbid insomnia and depression were administered zaleplon for 6 weeks. Insomnia severity was assessed using the Insomnia Severity Index and Epworth Sleepiness Scale, and depression severi

SUBMITTER: Goldschmied JR 

PROVIDER: S-EPMC8374930 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature